Apretude (cabotegravir extended-release injectable suspension) vs Sunlenca (lenacapavir)
Apretude (cabotegravir extended-release injectable suspension) vs Sunlenca (lenacapavir)
Apretude (cabotegravir extended-release injectable suspension) is an injectable form of HIV pre-exposure prophylaxis (PrEP) administered every two months, designed to reduce the risk of HIV infection in individuals who are at high risk but HIV-negative. Sunlenca (lenacapavir) is a long-acting HIV treatment option that can be used in combination with other antiretroviral medications for individuals who are HIV-positive with a history of treatment failure or resistance to multiple HIV drugs. When deciding between the two, it is important to consider that Apretude is for prevention in HIV-negative individuals, while Sunlenca is a treatment option for those already living with HIV, and the choice would depend on the individual's HIV status and treatment needs.
Difference between Apretude and Sunlenca
Metric | Apretude (cabotegravir extended-release injectable suspension) | Sunlenca (lenacapavir) |
---|---|---|
Generic name | Cabotegravir | Lenacapavir |
Indications | HIV prevention | HIV treatment |
Mechanism of action | Integrase inhibitor | HIV-1 capsid inhibitor |
Brand names | Apretude | Sunlenca |
Administrative route | Injection | Subcutaneous, Oral |
Side effects | Fever, fatigue, headache, musculoskeletal pain, sleep disorders, rash | Nausea, diarrhea, headache, muscle aches, injection site reactions |
Contraindications | Hypersensitivity to cabotegravir | Hypersensitivity to lenacapavir or any component of the formulation |
Drug class | Integrase strand transfer inhibitor (INSTI) | HIV-1 capsid inhibitor |
Manufacturer | ViiV Healthcare | Gilead Sciences |
Efficacy
Apretude (cabotegravir extended-release injectable suspension) for HIV/AIDS
Apretude (cabotegravir extended-release injectable suspension) is a medication approved by the U.S. Food and Drug Administration (FDA) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents who weigh at least 35 kilograms and are at risk of HIV. Apretude is not used for treatment but for prevention. Clinical trials have shown that Apretude is highly effective in reducing the risk of HIV infection. In a study comparing Apretude with daily oral emtricitabine/tenofovir disoproxil fumarate (Truvada), Apretude was found to be superior in preventing HIV acquisition.
Sunlenca (lenacapavir) for HIV/AIDS
Sunlenca (lenacapavir) is a novel antiretroviral medication developed for the treatment of HIV/AIDS. It belongs to a class of drugs known as capsid inhibitors, which work by interfering with the HIV capsid structure, an essential protein for viral replication. Sunlenca is designed for use in combination with other antiretroviral drugs for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. The efficacy of Sunlenca has been demonstrated in clinical trials, showing significant reductions in viral load and an increase in CD4+ cell counts in individuals with multidrug-resistant HIV.
Comparative Efficacy in Clinical Trials
When comparing the efficacy of Apretude and Sunlenca, it is important to note that they serve different purposes in HIV management. Apretude is a preventive medication, while Sunlenca is used for treatment. In their respective clinical trials, both medications have shown high efficacy rates in their designated roles. Apretude's efficacy as PrEP has been established as superior to oral Truvada, while Sunlenca has shown promise in treating individuals with limited treatment options due to resistance to multiple other antiretroviral drugs.
Conclusion on Efficacy
In conclusion, both Apretude and Sunlenca represent significant advancements in the fight against HIV/AIDS. Apretude offers an effective alternative to daily oral PrEP regimens, potentially increasing adherence and reducing the risk of HIV infection. Sunlenca provides a new hope for individuals with multidrug-resistant HIV, expanding the arsenal of treatments available to manage the disease effectively. The efficacy of these medications underscores the importance of ongoing research and development in HIV therapy to improve patient outcomes and quality of life.
Regulatory Agency Approvals
Apretude
Sunlenca
Access Apretude or Sunlenca today
If Apretude or Sunlenca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us